Search alternatives:
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1241
-
1242
-
1243
VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival.
Published 2018“…<b>(D)</b> HR [hazard ratio] of 1.72, p<1x10<sup>-16</sup>). <b>(E)</b> Similar analysis of 2,061 patients with ER<sup>+</sup> breast cancer (HR 1.48, p = 5.5x10<sup>-6</sup>). …”
-
1244
-
1245
-
1246
Ibuprofen and diclofenac decrease proliferation.
Published 2015“…<p>Proliferation was analyzed using crystal violet staining and results were verified via the CyQuant Direct Cell Proliferation assay in HTZ-349. (A) Starting at 72 h, all ibuprofen concentrations (0.5, 1, 2 mM) resulted in significant reduction of HTZ-349 proliferation (compared to non-treated Ctrl, 95% CI, p < 0.05). 2 mM ibuprofen caused significant proliferation inhibition at 24 h (0.01 > p ≤ 0.001) and 48 h (p < 0.0001). …”
-
1247
-
1248
-
1249
WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression.
Published 2024“…</b> RT-qPCR of WT1, p<0.05(*), vFLIP(ns), LANA, p<0.0001(****), K8.1, p<0.0001(****), and BCL2 p<0.05(*) in the setting of WT1 knockdown in ISLK BAC-16 with WT1 siRNA in comparison to a control siRNA using two-sided, unpaired student’s t-tests. …”
-
1250
-
1251
Decreased 11ß-HSD1 protein level by IGF-I overexpression <i>in vivo</i> and a direct treatment with IGF-I.
Published 2015“…<p><b>A</b>. IGF-I overexpression decreased the levels of 11ß-HSD1 in pancreatic islets, liver and visceral fat, shown in Western blots. …”
-
1252
Annual number of outpatient visits in recurrence and non-recurrence groups.
Published 2025“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
1253
Clinical and genetic characteristics of 5 patients harboring mutations in the <i>NR5A1</i> gene.
Published 2014Subjects: -
1254
-
1255
Parvalbumin-positive interneurons (PV-INs) in perilesional tissue respond to optogenetic stimulation and are involved in voluntary movement, but show a decreased firing rate.
Published 2025“…Data are shown as mean ± SEM. Created in BioRender. Vignozzi, L. (2025) <a href="https://BioRender.com/md8zh2c" target="_blank">https://BioRender.com/md8zh2c</a>. …”
-
1256
A Yoga Strengthening Program Designed to Minimize the Knee Adduction Moment for Women with Knee Osteoarthritis: A Proof-Of-Principle Cohort Study
Published 2015“…A secondary objective was to determine whether the program could improve mobility and fitness, and decrease peak KAM during gait. …”
-
1257
CII, inhibitor of SphK, decreases both the migration of HPAECs in a scratch assay <i>in vitro</i> and the content of S1P in HPAECs.
Published 2013“…<p>HPAECs grown to ∼95% confluence in 35 mm dishes were starved for 3 h in 0.1% FBS in EBM-2 without growth factors and treated with 10 µM of CII. …”
-
1258
-
1259
-
1260